Accounting Policies, by Policy (Policies)	12 Months Ended
	May 31, 2012
Basis of Accounting, Policy [Policy Text Block]	Nature of Business - Founded in 1982, Immucor, Inc., a Georgia corporation ("Immucor" or the "Company"), develops, manufactures and sells a complete line of reagents and automated systems used primarily by hospitals, reference laboratories and donor centers in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood used for blood transfusion.The Company operates manufacturing facilities in North America with both direct affiliate offices and third-party distribution arrangements worldwide.
Consolidation, Policy [Policy Text Block]	Consolidation Policy - The consolidated financial statements include the accounts of the Company and all of its subsidiaries.All significant inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.Actual results could differ from those estimates.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation - Consistent with the provisions of ASC 718, "Compensation - Stock Compensation," compensation cost for grants of all share-based payments is based on the estimated grant date fair value.The value of share-based compensation is attributed to expense using the straight-line method. The fair value of the Company's share-based payment awards for the Successor fiscal periods is estimated using a Monte Carlo simulation approach. The Monte Carlo method is used to calculate the fair value of an option with multiple sources of uncertainty by creating random price paths for the underlying share and expected future value, then discounting the average of those paths to determine the fair value.Key input assumptions used to estimate the fair value of stock options and stock appreciation rights include the initial value of common stock, expected term until the exercise of the equity award, the expected volatility of the equity, risk-free rates of return and dividend yields, if any. The fair value of the Company's share-based payment awards for the Predecessor fiscal periods was estimated using the Black-Scholes option-pricing model (the "Black-Scholes model"). The Black-Scholes model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.The Black-Scholes model requires the input of certain assumptions, and changes in the assumptions could have materially affected the fair value estimates. The Company calculated its additional paid in capital pool ("APIC pool") based on the actual income tax benefits received from exercises of share-based compensation awards granted after the effective date of ASC 718 using the long method. As of the date of the Acquisition, the APIC pool was reset to zero.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and trade accounts receivable. In order to mitigate the concentration of credit risk, the Company places its cash and cash equivalents with multiple financial institutions. Cash and cash equivalents were $18.6 million and $302.6 million at May 31, 2012 and 2011, respectively, with approximately 43% and 83% of it located in the U.S. Concentrations of credit risk with respect to trade accounts receivable are limited because a large number of geographically diverse customers make up the Company's customer base, thus spreading the trade credit risk. At May 31, 2012, 2011 and 2010, no single customer or group of customers represented more than 10% of total consolidated net sales or trade accounts receivable. The Company controls credit risk through credit limits and monitoring procedures. At May 31, 2012 and 2011, the Company's net trade accounts receivable balances were $66.4 million and $63.3 million, respectively, with about 58% of these accounts being of foreign origin, predominantly European.Companies and government agencies in some European countries require longer payment terms as a part of doing business.This may subject the Company to a higher risk of uncollectibility.This risk is considered when the allowance for doubtful accounts is evaluated. The Company generally does not require collateral from its customers. Concentration of Production Facilities and Supplies - Substantially all of the Company's reagent products are produced in its Norcross, Georgia facility in the U.S., and its reagent production is highly dependent on the uninterrupted and efficient operation of this facility.Therefore, if a catastrophic event occurred at the Norcross facility, such as a fire or tornado or if there is a production disruption for an extended period for any other reason, many of those products could not be produced until the manufacturing portion of the facility is restored and cleared by the FDA.The Company maintains a disaster plan to minimize the effects of such a catastrophe, and the Company has obtained insurance to protect against certain business interruption losses. While the Company purchases certain raw materials from a single supplier, the Company has reliable supplies of most raw materials.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents - The Company considers deposits that can be redeemed on demand and investments with an original maturity of three months or less when purchased to be cash and cash equivalents. Generally, cash and cash equivalents held at financial institutions are in excess of insurance limit. The Company limits its exposure to credit loss by placing its cash and cash equivalents in liquid investments with high quality financial institutions.
Inventory, Policy [Policy Text Block]	Inventories - Typically, inventories are stated at the lower of cost (first-in, first-out basis) or market (net realizable value).Cost includes material, labor and manufacturing overhead.The Company also allocates certain production-related general and administrative costs to inventory and incurred approximately $3.2 million, $0.9 million, $2.8 million, and $3.3 million of such costs in Successor fiscal 2012 period, the Predecessor fiscal 2012 period, and the fiscal years ended May 31, 2011 and 2010, respectively. The Company had approximately $1.1 million and $0.9 million of general and administrative costs remaining in inventory as of May 31, 2012 and May 31, 2011, respectively. The Company uses a standard cost system as a tool to monitor production efficiency.The standard cost system applies estimated labor and manufacturing overhead factors to inventory based on budgeted production and efficiency levels, staffing levels and costs of operation, based on the experience and judgment of management.Actual costs and production levels may vary from the standard established and such variances are charged to the consolidated statement of operations as a component of cost of sales.Since U.S. generally accepted accounting principles require that the standard cost approximate actual cost, periodic adjustments are made to the standard rates to approximate actual costs. In connection with the Acquisition of the Company on August 19, 2011, a fair value adjustment of $24.4 million increased inventory to fair value, which was greater than replacement cost.As of May 31, 2012, all of the fair value adjustment has been expensed through cost of sales in the Successor fiscal 2012 period, and the inventory is again stated at the lower of cost (first-in, first-out basis) or market (net realizable value). No material changes have been made to the inventory policy during fiscal 2012, 2011 or 2010.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments - The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, trade accounts receivable, accounts payable and derivatives approximate their fair values.
Derivatives, Policy [Policy Text Block]	Derivative Instruments - The Company may from time to time use derivatives as a risk management tool to mitigate the potential impact of interest rate and foreign exchange risk.All derivatives are carried at fair value in our consolidated balance sheets.The Company does not enter into speculative derivatives.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment - Property, plant and equipment is stated at cost less accumulated depreciation.Expenditures for replacements are capitalized, and the replaced items are retired.Normal maintenance and repairs are charged to operations.Major maintenance and repair activities that significantly enhance the useful life of the asset are capitalized. When property and equipment are retired, sold, or otherwise disposed of, the asset's carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is included in operations.Depreciation is computed using the straight-line method over the estimated lives of the related assets ranging from three to thirty years.Carrying values of these assets are evaluated if impairment indicators arise.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill - Consistent with ASC 350, "Intangibles - Goodwill and Other," goodwill and intangible assets with indefinite lives are not amortized but are tested for impairment annually or more frequently if impairment indicators arise.Intangible assets that have finite lives are amortized over their useful lives. The Company evaluates the carrying value of goodwill during the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating whether goodwill is impaired the Company first assesses qualitative factors to determine if it is more likely than not (defined as 50% or more) that the fair value of the reporting unit is less than its carrying amount.If it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, no additional steps are taken.In certain cases, it is more practicable to compare the fair value of the reporting unit to which the goodwill is assigned to the reporting unit's carrying amount, including goodwill.The fair value of the reporting unit is estimated using primarily the income, or discounted cash flows, approach. If the carrying amount of a reporting unit exceeds its fair value, then the amount of the impairment loss must be measured.The impairment loss would be calculated by comparing the implied fair value of the reporting unit's goodwill to its carrying amount.In calculating the implied fair value of the reporting unit's goodwill, the fair value of the reporting unit is allocated to all of the other assets and liabilities of that unit based on their fair values.The excess of the fair value of a reporting unit over the amount assigned to its other assets and liabilities is the implied fair value of goodwill. An impairment loss would be recognized when the carrying amount of goodwill exceeds its implied fair value. The Company's evaluation of goodwill and intangible assets with indefinite lives completed during fiscal years 2012, 2011 and 2010 resulted in no impairment charges. Other Intangible Assets - Other intangible assets primarily includes customer lists, deferred licensing costs, existing technology and trade names.These intangible assets are amortized over their useful lives.Carrying values of these assets are evaluated when impairment indicators arise.There was no impairment charge related to other intangible assets in fiscal years 2012, 2011 or 2010. In-process research and development ("IPR&D") is also included in other intangible assets.IPR&D has an indefinite life until the completion or abandonment of the individual project.When a project is completed, its value will be amortized over the useful life.If a project is abandoned, its value is written off.The carrying value of IPR&D is tested for impairment annually or more frequently if impairment indicators arise.There was no impairment charge related to IPR&D during fiscal 2012, 2011 or 2010.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation - The financial statements of foreign subsidiaries have been translated into U.S. Dollars in accordance with ASC 830-30, "Translation of Financial Statements" ("ASC 830-30").The financial position and results of operations of the Company's foreign subsidiaries are measured using the foreign subsidiary's local currency as the functional currency. Revenues and expenses of such subsidiaries have been translated into U.S. Dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of shareholders' equity, unless there is a sale or complete liquidation of the underlying foreign investments. Foreign currency translation adjustments resulted in losses of $18.4 million in the Successor fiscal 2012 period, losses of $2.2 million in the Predecessor fiscal 2012 period, gains of $13.9 million in fiscal 2011 and losses of $5.2 million in fiscal 2010. Gains and losses that result from foreign currency transactions are included in "other non-operating income (expense)" in the consolidated statements of operations. In the Successor fiscal 2012 period and the Predecessor fiscal 2012 period net foreign currency transaction gains of $0.4 million and $2.7 million, respectively, were recorded.During the fiscal years ended May 31, 2011 and 2010, net foreign currency transaction losses of $0.3 million and $0.4 million, respectively, were incurred.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition - The Company recognizes revenue in accordance with ASC 605, "Revenue Recognition," when the following four basic criteria have been met:(1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services are rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured.Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected. The Company's revenue is primarily generated from the following types of arrangements: Instrument sales arrangements, which includes the sale of instruments, reagents, consumables (parts kits), training, and general support services Instrument lease arrangements, which includes the lease of instruments and the sale of reagents Reagent sales Effective June 1, 2012, the Company prospectively adopted ASU 2009-13, "Multiple Element Revenue Arrangements."Under the historical standards, the Company used the residual method to allocate arrangement consideration when vendor-specific objective evidence ("VSOE") existed for an undelivered element, but not for the delivered elements.Under the new standards, the Company allocates revenue to all deliverables based on their relative selling prices.The Company uses the following hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) VSOE of fair value, (ii) third-party evidence of selling price ("TPE"), and (iii) management's best estimate of selling price ("MBESP").VSOE generally exists only when the Company sells the deliverable separately and is the price actually charged by the Company for that deliverable.TPE represents the selling price of a similar product or service by another vendor.MBESPs reflect management's best estimates of what the selling prices of elements would be if they were sold regularly on a stand-alone basis.The adoption of this accounting standard update did not have a material impact on the consolidated financial statements. Instrument Sales Arrangements The Company enters into contractual obligations to sell instruments, reagents, consumable parts kits, training, and general support services.The selling price of each of the elements is used for purposes of allocating total contract consideration on a relative selling price basis, and the related timing of revenue recognition of each of the elements is as follows: Reagents (without price guarantees) - the selling price of reagents (without price guarantees) is based on VSOE of fair value by reference to the price our customers are required to pay for the reagents when sold separately. Reagents (with price guarantees) - the selling price of reagents (with price guarantees) is based on MBESP.In determining MBESP, the Company considers the following: (1) pricing practices as they relate to future price increases, (2) the overall economic conditions, and (3) competitor pricing. Revenue from the sale of the Company's reagents (both with and without price guarantees) to end users is primarily recognized upon shipment when both title and risk of loss transfer to the customer, unless there are specific contractual terms to the contrary.Revenue from the sale of the Company's reagents to distributors is recognized FOB customs clearance when both title and risk of loss transfer to the customer. Instrument sales - the selling price of our instruments is based on MBESP.In determining MBESP, the Company considers the following: (1) the overall economic conditions, (2) the expected profit margin to be realized on the instruments, and (3) competitor pricing.Revenue from instrument sales is recognized when the instrument has been installed and accepted by the customer. Consumables (part kits) - the selling price of consumables is based on MBESP.In determining MBESP, the Company considers the following: (1) the overall economic conditions, (2) the expected profit margin to be realized on the agreement, and (3) competitor pricing.Revenue from consumables is recognized when the consumables have been delivered. Training - the selling price of training is based on MBESP.In determining MBESP, the Company considers the following: (1) the overall economic conditions, (2) the expected profit margin to be realized on the agreement, and (3) competitor pricing.Revenue from training services is recognized as the training services are provided. General Support Services - the selling price of general support services is based on VSOE by reference to the price our customers are required to pay for the general support services when sold separately via renewals.Revenue from general support services is recognized over the term of the agreement. Instrument Lease Arrangements The Company enters into contractual arrangements with customers to lease instruments, sell reagents and consumables (parts kits), and provide training and general support services.At the onset of the arrangement, total contract consideration is allocated to the various elements of the arrangement based on the elements' relative selling prices. On a monthly basis, revenue is reclassified using this allocation.The monthly revenue reclassification has no impact on revenue recognition, but allows management to capture revenue by element for purposes of segment reporting. The selling price of each of the elements is used for purposes of allocating total contract consideration on a relative selling price basis, and the related timing of revenue recognition of each of the elements is as follows: Instrument leases - the selling price of instrument leases is based on MBESP.In determining MBESP, the Company considers the following: (1) the overall economic conditions, (2) the expected profit margin to be realized on the agreement, and (3) competitor pricing.The total rental revenue determined on this basis is recognized ratably over the term of the operating lease, which is generally 60 months. Revenue from instrument leases is first recognized when the instrument has been installed and accepted by the customer. Reagents - the selling price of reagents is based on VSOE of fair value by reference to the price our customers are required to pay for the reagents when sold separately.Due to their short shelf life, reagents are shipped on a frequent and recurring basis.Revenue is primarily recognized upon shipment when both title and risk of loss transfer to the customer, unless there are specific contractual terms to the contrary. Consumables (part kits) - the selling price of our consumables is based on MBESP.In determining MBESP, the Company considers the following: (1) the overall economic conditions, (2) the expected profit margin to be realized on the agreement, and (3) competitor pricing.Revenue from consumables is recognized when the consumables have been delivered. Training - the selling price of training is based on MBESP.In determining MBESP, the Company considers the following: (1) the overall economic conditions, (2) the expected profit margin to be realized on the agreement, and (3) competitor pricing.Revenue from training services is recognized as the training services are provided. Reagent sales Revenue from standalone reagent sales is recognized when both the title and risk of loss transfer to the customer.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Charges and Sales Tax - The amounts billed to customers for shipping and handling of orders are classified as revenue and reported in the statements of operations as net sales.The costs of handling and shipping customer orders are reported in the operating expense section of the consolidated statements of operations as distribution expense. For the Successor fiscal 2012 period, the Predecessor fiscal 2012 period, and the fiscal years ended May 31, 2011 and May 31, 2010 these costs were $14.3 million, $4.0 million, $16.5 million and $14.8 million, respectively. Sales taxes invoiced to customers and payable to government agencies are recorded on a net basis with the sales tax portion of a sales invoice directly credited to a liability account and the balance of the invoice credited to a revenue account.
Receivables, Policy [Policy Text Block]	Trade Accounts Receivable and Allowance for Doubtful Accounts - Trade accounts receivables at May 31, 2012 and May 31, 2011 were $66.4 million and $63.3 million, respectively, and were net of allowances for doubtful accounts of $0.6 million and $2.2 million, respectively.The allowance for doubtful accounts represents a reserve for estimated losses resulting from the inability of the Company's customers to pay their debts. The collectibility of trade accounts receivable balances is regularly evaluated based on a combination of factors such as customer credit-worthiness, past transaction history with the customer, current economic industry trends and changes in customer payment patterns. If it is determined that a customer will be unable to fully meet its financial obligation, such as in the case of a bankruptcy filing or other material events impacting its business, a specific allowance for doubtful accounts is recorded to reduce the related receivable to the amount expected to be recovered. On August 19, 2011, in connection with the Acquisition of the Company, trade accounts receivables were written down to the amount expected to be recovered and the allowance for doubtful accounts was set to zero.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs - Advertising costs are expensed as incurred and are classified as selling and marketing operating expenses in the consolidated statements of operations.Advertising expenses were $0.2 million, $0.1 million, $0.5 million and $0.6 million for the Successor fiscal 2012 period, the Predecessor fiscal 2012 period, and the fiscal years ended May 31, 2011 and 2010, respectively.
Research, Development, and Computer Software, Policy [Policy Text Block]	Research and Development costs - Research and development costs are expensed as incurred and are disclosed as a separate line item in the consolidated statements of operations.
Commitments and Contingencies, Policy [Policy Text Block]	Loss contingencies - Certain conditions may exist as of the date the financial statements are issued that may result in a loss to the Company, but which will only be determined and resolved when one or more future events occur or fail to occur. The Company's management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss is likely to occur and the amount of the liability can be estimated, then the estimated liability is accrued in the Company's financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not accrued or disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Legal costs relating to loss contingencies are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes - Effective with the Acquisition, the Company's taxable income or loss is included in the consolidated income tax returns of Holdings.Current and deferred income taxes are allocated to the members of the consolidated group as if each member were a separate taxpayer. Deferred income taxes are computed using the asset and liability method.The Company records the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carry-forwards. The value of the Company's deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in applicable tax jurisdictions, based on estimates and assumptions. If these estimates and related assumptions change in the future, the Company may be required to record additional valuation allowances against its deferred tax assets resulting in additional income tax expense in the Company's consolidated statements of operations. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized, and the Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry-back opportunities, and tax-planning strategies in making this assessment.Management assesses the need for additional valuation allowances quarterly. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of complex tax laws. Although ASC 740, "Income Taxes," provides clarification on the accounting for uncertainty in income taxes recognized in the financial statements, the threshold and measurement attribute will continue to require significant judgment by management. Resolution of these uncertainties in a manner inconsistent with the Company's expectations could have a material impact on its results of operations.
New Accounting Pronouncements, Policy [Policy Text Block]	Impact of Recently Issued Accounting Standards - Adopted by the Company in fiscal 2012 In October 2009, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2009-13, "Multiple Deliverables Revenue Arrangements", which is an amendment of ASC 605-25, "Revenue Recognition: Multiple Element Arrangements." This update addresses the accounting for multiple-deliverable arrangements to allow the vendor to account for deliverables separately instead of as one combined unit by amending the criteria for separating consideration in multiple-deliverable arrangements. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on (a)vendor-specific objective evidence, (b)third-party evidence or (c)best estimate of selling price. The residual method of allocation has been eliminated and arrangement consideration is now required to be allocated to all deliverables at the inception of the arrangement using the selling price method. Additionally, expanded disclosures are required relating to multiple deliverable revenue arrangements. This update is effective for fiscal years beginning on or after June15, 2010. The adoption of ASU 2009-13 during the first quarter of fiscal 2012 did not have a material impact on the Company's consolidated financial statements. In September 2011, the FASB issued ASU 2011-08, "Testing Goodwill for Impairment", which simplifies testing for impairment by allowing an entity to first assess qualitative factors and determine if it is more likely than not (defined as 50% or more) that the fair value of the reporting unit is less than its carrying amount. That determination can then be used to decide if it is necessary to perform the two-step goodwill impairment test. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December15, 2011, which corresponds to the Company's first quarter of fiscal 2013. Early adoption is permitted in certain circumstances. The Company early adopted ASU 2011-08 during the fourth quarter of the current fiscal year and this adoption did not have a material impact on the Company's consolidated financial statements. Not yet adopted by the Company In December 2011, the FASB issued ASU 2011-11, "Disclosures about Offsetting Assets and Liabilities" which requires an entity to disclose information about offsetting and related arrangements to ensure that the users of the Company's financial statements can understand the effect that offsetting has on the Company's financial position.ASU 2001-11 is effective for annual periods beginning on or after January 1, 2013, which corresponds to the Company's first quarter of fiscal 2014.Retrospective application is required for all comparative periods presented.The adoption of ASU 2011-11 is not expected to have a material impact on the Company's consolidated financial statements. In June 2011, the FASB issued ASU 2011-05, "Presentation of Comprehensive Income", which was issued to enhance comparability between entities that report under U.S. GAAP and IFRS, and to provide a more consistent method of presenting non-owner transactions that affect an entity's equity. ASU 2011-05 eliminates the option to report other comprehensive income and its components in the statement of changes in stockholders' equity and requires an entity to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement or in two separate but consecutive statements. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December15,2011, which corresponds to the Company's first quarter of fiscal 2013. Early adoption of the new guidance is permitted and full retrospective application is required. The adoption of ASU 2011-05 is not expected to have a material impact on the Company's consolidated financial statements. In December 2011, the FASB issued ASU2011-12, "Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No.2011-05", which deferred the guidance on whether to require entities to present reclassification adjustments out of accumulated other comprehensive income by component in both the statement where net income is presented and the statement where other comprehensive income is presented for both interim and annual financial statements. ASU2011-12 reinstated the requirements for the presentation of reclassifications that were in place prior to the issuance of ASU 2011-05 and did not change the effective date for ASU 2011-05. For public entities, the amendments in ASU 2011-05 and ASU 2011-12 are effective for fiscal years, and interim periods within those years, beginning after December15, 2011, and should be applied retrospectively. The adoption of ASU 2011-12 is not expected to have a material impact on the Company's consolidated financial statements. The FASB issues ASUs to amend the authoritative literature in the Accounting Standards Codification.There have been a number of ASUs to date that amend the original text of the ASC.Except for those listed above, those issued to date either (i) provide supplemental guidance, (ii) are technical corrections or (iii) are not applicable to the Company.Additionally, there were various other accounting standards and interpretations issued during the fiscal year ended May 31, 2012 that the Company has not been required to adopt, none of which is expected to have a material impact on the Company's consolidated financial statements and the notes thereto going forward.